Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): Effects on RSV susceptibility to palivizumab

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 635-638

  Zhu, Qing ^a   Patel, Nita K ^a   McAuliffe, Josephine M ^a   Zhu, Wei ^a   Wachter, Leslie ^a   McCarthy, Michael P ^a   Suzich, Joann A ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HYBRID PROTEIN; PALIVIZUMAB;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE MUTATION; GENETIC POLYMORPHISM; IMMUNOPROPHYLAXIS; INCIDENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; EPITOPES; HUMANS; INFANT; INFANT, NEWBORN; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84856255621     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir790     Document Type: Article

References (13)

1. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 2003; 22:S13-20. (Pubitemid 36230941)
2. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498-505.
3. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203.
4. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307:397-400. (Pubitemid 12089293)
5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531-7.
6. Crowe JE, Firestone CY, Crim R, et al. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Viorlogy 1998; 252:373-5. (Pubitemid 29013419)
7. Zhao X, Chen FP, Sullender WM. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004; 318:608-12. (Pubitemid 38224303)
8. Zhao X, Liu E, Chen FP, Sullender WM. In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol 2006; 80:11651-7. (Pubitemid 44801467)
9. Zhu Q, McAuliffe JM, Patel NK, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect. Dis 2011; 203:674-82.
10. Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol 2008; 42:52-7.
11. Adams O, Bonzel L, Kovacevic A, et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010; 51:185-8.
12. Jin H, Clarke D, Zhou HZ, et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 1998; 251:206-14. (Pubitemid 28527732)
13. Papenburg J, Carbonneau J, Hamelin M, et al. Molecular evolution of respiratory syncytial virus fusion gene and surveillance for mutations in the palivizumab binding site, Canada, 2006-2010. Emerg Infect Dis. In press.